ProKidney Corp. (PROK) stock
PROKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.10+0.06 (+5.77%)
Close on Nov 17, 2026Market cap $332.56MP/E –Yield –
ProKidney operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
ProKidney's operating cash flow for the twelve months ending Jun 30, 2026 was -$141.17M. For fiscal 2025 it was -$120.12M. The highest annual figure on record is -$25.18M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$120.12M | – |
| FY2024 | Dec 31, 2024 | -$126.35M | – |
| FY2023 | Dec 31, 2023 | -$90.07M | – |
| FY2022 | Dec 31, 2022 | -$77.09M | – |
| FY2021 | Dec 31, 2021 | -$50.30M | – |
| FY2020 | Dec 31, 2020 | -$25.18M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$40.37M | – |
| Q1 FY2026 | Mar 31, 2026 | -$41.68M | – |
| Q4 FY2025 | Dec 31, 2025 | -$32.51M | – |
| Q3 FY2025 | Sep 30, 2025 | -$26.60M | – |
| Q2 FY2025 | Jun 30, 2025 | -$31.42M | – |
| Q1 FY2025 | Mar 31, 2025 | -$29.59M | – |
| Q4 FY2024 | Dec 31, 2024 | -$24.17M | – |
| Q3 FY2024 | Sep 30, 2024 | -$29.24M | – |
| Q2 FY2024 | Jun 30, 2024 | -$38.29M | – |
| Q1 FY2024 | Mar 31, 2024 | -$34.65M | – |
| Q4 FY2023 | Dec 31, 2023 | -$25.38M | – |
| Q3 FY2023 | Sep 30, 2023 | -$23.78M | – |
| Q2 FY2023 | Jun 30, 2023 | -$14.92M | – |
| Q1 FY2023 | Mar 31, 2023 | -$25.99M | – |
| Q4 FY2022 | Dec 31, 2022 | -$15.76M | – |
| Q3 FY2022 | Sep 30, 2022 | -$22.84M | – |
| Q2 FY2022 | Jun 30, 2022 | -$23.03M | – |
| Q1 FY2022 | Mar 31, 2022 | -$15.46M | – |
| Q4 FY2021 | Dec 31, 2021 | -$12.99M | – |
See a number that looks wrong?